TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...

Tonix Pharmaceuticals Holding Corp. announced that the FDA has set a PDUFA goal date of August 15, 2025, for TNX-102 SL, which, if approved, would be the first new drug for fibromyalgia in over 15 ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration will not require an Advisory Committee meeting to discuss the ...

Their drug TNX-102 SL* (cyclobenzaprine HCl sublingual tablets), a non-opioid investigational drug targeting fibromyalgia, which affects millions of Americans, mostly women. This type of pain ...

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...

The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

“Tonix is debt-free and expects to have sufficient cash to fund operations through the PDUFA target date of August 15, 2025, and the anticipated commercial launch of TNX-102 SL in the fourth quarter ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.